nach oben

Erschienen in:

01.07.2022 | Non-Thematic Review

Role of Neuropilin-2-mediated signaling axis in cancer progression and therapy resistance

verfasst von: Ridwan Islam, Juhi Mishra, Sanika Bodas, Sreyashi Bhattacharya, Surinder K. Batra, Samikshan Dutta, Kaustubh Datta

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 3/2022

Einloggen, um Zugang zu erhalten

Abstract

Neuropilins (NRPs) are transmembrane proteins involved in vascular and nervous system development by regulating angiogenesis and axon guidance cues. Several published reports have established their role in tumorigenesis. NRPs are detectable in tumor cells of several cancer types and participate in cancer progression. NRP2 is also expressed in endothelial and immune cells in the tumor microenvironment and promotes functions such as lymphangiogenesis and immune suppression important for cancer progression. In this review, we have taken a comprehensive approach to discussing various aspects of NRP2-signaling in cancer, including its regulation, functional significance in cancer progression, and how we could utilize our current knowledge to advance the studies and target NRP2 to develop effective cancer therapies.

York, J. R., Yuan, T., Lakiza, O., McCauley, D. W. (2018). An ancestral role for semaphorin3F-neuropilin signaling in patterning neural crest within the new vertebrate head. Development 145. (14). https://doi.org/10.1242/dev.164780.

Takahashi, T., Nakamura, F., Jin, Z., Kalb, R. G., & Strittmatter, S. M. (1998). Semaphorins A and E act as antagonists of neuropilin-1 and agonists of neuropilin-2 receptors. Nature Neuroscience, 1(6), 487–493. https://doi.org/10.1038/2203CrossRefPubMed

Bae, D., Lu, S., Taglienti, C. A., & Mercurio, A. M. (2008). Metabolic stress induces the lysosomal degradation of neuropilin-1 but not neuropilin-2. Journal of Biological Chemistry, 283(42), 28074–28080. https://doi.org/10.1074/jbc.M804203200CrossRefPubMedPubMedCentral

Bielenberg, D. R., Pettaway, C. A., Takashima, S., & Klagsbrun, M. (2006). Neuropilins in neoplasms: Expression, regulation, and function. Experimental Cell Research, 312(5), 584–593. https://doi.org/10.1016/j.yexcr.2005.11.024CrossRefPubMed

Pellet-Many, C., Frankel, P., Jia, H., & Zachary, I. (2008). Neuropilins: Structure, function and role in disease. The Biochemical Journal, 411(2), 211–226.CrossRef

Wild, J. R., Staton, C. A., Chapple, K., & Corfe, B. M. (2012). Neuropilins: Expression and roles in the epithelium. International Journal of Experimental Pathology, 93(2), 81–103. https://doi.org/10.1111/j.1365-2613.2012.00810.xCrossRefPubMedPubMedCentral

Cai, H., & Reed, R. R. (1999). Cloning and characterization of neuropilin-1-interacting protein: A PSD-95/Dlg/ZO-1 domain-containing protein that interacts with the cytoplasmic domain of neuropilin-1. Journal of Neuroscience, 19(15), 6519–6527.CrossRef

Parker, M. W., Linkugel, A. D., Goel, H. L., Wu, T., Mercurio, A. M., & Vander Kooi, C. W. (2015). Structural basis for VEGF-C binding to neuropilin-2 and sequestration by a soluble splice form. Structure., 23(4), 677–687. https://doi.org/10.1016/j.str.2015.01.018CrossRefPubMedPubMedCentral

Kolodkin, A. L., Levengood, D. V., Rowe, E. G., Tai, Y. T., Giger, R. J., & Ginty, D. D. (1997). Neuropilin is a semaphorin III receptor. Cell, 90(4), 753–762. https://doi.org/10.1016/s0092-8674(00)80535-8CrossRefPubMed

10.

He, Z., & Tessier-Lavigne, M. (1997). Neuropilin is a receptor for the axonal chemorepellent Semaphorin III. Cell, 90(4), 739–751. https://doi.org/10.1016/s0092-8674(00)80534-6CrossRefPubMed

11.

Chen, H., Chedotal, A., He, Z., Goodman, C. S., & Tessier-Lavigne, M. (1997). Neuropilin-2, a novel member of the neuropilin family, is a high affinity receptor for the semaphorins Sema E and Sema IV but not Sema III. Neuron, 19(3), 547–559. https://doi.org/10.1016/s0896-6273(00)80371-2CrossRefPubMed

12.

Giger, R. J., Urquhart, E. R., Gillespie, S. K., Levengood, D. V., Ginty, D. D., & Kolodkin, A. L. (1998). Neuropilin-2 is a receptor for semaphorin IV: Insight into the structural basis of receptor function and specificity. Neuron, 21(5), 1079–1092. https://doi.org/10.1016/s0896-6273(00)80625-xCrossRefPubMed

13.

Karpanen, T., Heckman, C. A., Keskitalo, S., Jeltsch, M., Ollila, H., Neufeld, G., Tamagnone, L., & Alitalo, K. (2006). Functional interaction of VEGF-C and VEGF-D with neuropilin receptors. The FASEB Journal, 20(9), 1462–1472. https://doi.org/10.1096/fj.05-5646comCrossRefPubMed

14.

Favier, B., Alam, A., Barron, P., Bonnin, J., Laboudie, P., Fons, P., Mandron, M., Herault, J. P., Neufeld, G., Savi, P., Herbert, J. M., & Bono, F. (2006). Neuropilin-2 interacts with VEGFR-2 and VEGFR-3 and promotes human endothelial cell survival and migration. Blood, 108(4), 1243–1250. https://doi.org/10.1182/blood-2005-11-4447CrossRefPubMed

15.

Caunt, M., Mak, J., Liang, W. C., Stawicki, S., Pan, Q., Tong, R. K., Kowalski, J., Ho, C., Reslan, H. B., Ross, J., Berry, L., Kasman, I., Zlot, C., Cheng, Z., Le Couter, J., Filvaroff, E. H., Plowman, G., Peale, F., French, D., … Bagri, A. (2008). Blocking neuropilin-2 function inhibits tumor cell metastasis. Cancer Cell, 13(4), 331–342. https://doi.org/10.1016/j.ccr.2008.01.029CrossRefPubMed

16.

Xu, Y., Yuan, L., Mak, J., Pardanaud, L., Caunt, M., Kasman, I., Larrivee, B., Del Toro, R., Suchting, S., Medvinsky, A., Silva, J., Yang, J., Thomas, J. L., Koch, A. W., Alitalo, K., Eichmann, A., & Bagri, A. (2010). Neuropilin-2 mediates VEGF-C-induced lymphatic sprouting together with VEGFR3. Journal of Cell Biology, 188(1), 115–130. https://doi.org/10.1083/jcb.200903137CrossRefPubMedPubMedCentral

17.

Rossignol, M., Gagnon, M. L., & Klagsbrun, M. (2000). Genomic organization of human neuropilin-1 and neuropilin-2 genes: Identification and distribution of splice variants and soluble isoforms. Genomics, 70(2), 211–222. https://doi.org/10.1006/geno.2000.6381CrossRefPubMed

18.

Geretti, E., van Meeteren, L. A., Shimizu, A., Dudley, A. C., Claesson-Welsh, L., & Klagsbrun, M. (2010). A mutated soluble neuropilin-2 B domain antagonizes vascular endothelial growth factor bioactivity and inhibits tumor progression. Molecular Cancer Research, 8(8), 1063–1073. https://doi.org/10.1158/1541-7786.MCR-10-0157CrossRefPubMed

19.

Immormino, R. M., Lauzier, D. C., Nakano, H., Hernandez, M. L., Alexis, N. E., Ghio, A. J., Tilley, S. L., Doerschuk, C. M., Peden, D. B., Cook, D. N., & Moran, T. P. (2018). Neuropilin-2 regulates airway inflammatory responses to inhaled lipopolysaccharide. American Journal of Physiology. Lung Cellular and Molecular Physiology, 315(2), L202–L211. https://doi.org/10.1152/ajplung.00067.2018CrossRefPubMedPubMedCentral

20.

Chen, H., He, Z., Bagri, A., & Tessier-Lavigne, M. (1998). Semaphorin-neuropilin interactions underlying sympathetic axon responses to class III semaphorins. Neuron, 21(6), 1283–1290. https://doi.org/10.1016/s0896-6273(00)80648-0CrossRefPubMed

21.

Yuan, L., Moyon, D., Pardanaud, L., Breant, C., Karkkainen, M. J., Alitalo, K., & Eichmann, A. (2002). Abnormal lymphatic vessel development in neuropilin 2 mutant mice. Development, 129(20), 4797–4806.CrossRef

22.

Giger, R. J., Cloutier, J. F., Sahay, A., Prinjha, R. K., Levengood, D. V., Moore, S. E., Pickering, S., Simmons, D., Rastan, S., Walsh, F. S., Kolodkin, A. L., Ginty, D. D., & Geppert, M. (2000). Neuropilin-2 is required in vivo for selective axon guidance responses to secreted semaphorins. Neuron, 25(1), 29–41. https://doi.org/10.1016/s0896-6273(00)80869-7CrossRefPubMed

23.

Neufeld, G., Cohen, T., Shraga, N., Lange, T., Kessler, O., & Herzog, Y. (2002). The neuropilins: Multifunctional semaphorin and VEGF receptors that modulate axon guidance and angiogenesis. Trends in Cardiovascular Medicine, 12(1), 13–19. https://doi.org/10.1016/s1050-1738(01)00140-2CrossRefPubMed

24.

Sahay, A., Molliver, M. E., Ginty, D. D., & Kolodkin, A. L. (2003). Semaphorin 3F is critical for development of limbic system circuitry and is required in neurons for selective CNS axon guidance events. Journal of Neuroscience, 23(17), 6671–6680.CrossRef

25.

Lumb, R., Wiszniak, S., Kabbara, S., Scherer, M., Harvey, N., & Schwarz, Q. (2014). Neuropilins define distinct populations of neural crest cells. Neural Development, 9, 24. https://doi.org/10.1186/1749-8104-9-24CrossRefPubMedPubMedCentral

26.

Shiflett, M. W., Gavin, M., & Tran, T. S. (2015). Altered hippocampal-dependent memory and motor function in neuropilin 2-deficient mice. Translational Psychiatry, 5, e521. https://doi.org/10.1038/tp.2015.17CrossRefPubMedPubMedCentral

27.

Siemerink, M. J., Klaassen, I., Vogels, I. M., Griffioen, A. W., Van Noorden, C. J., & Schlingemann, R. O. (2012). CD34 marks angiogenic tip cells in human vascular endothelial cell cultures. Angiogenesis, 15(1), 151–163. https://doi.org/10.1007/s10456-011-9251-zCrossRefPubMedPubMedCentral

28.

Coma, S., Allard-Ratick, M., Akino, T., van Meeteren, L. A., Mammoto, A., & Klagsbrun, M. (2013). GATA2 and Lmo2 control angiogenesis and lymphangiogenesis via direct transcriptional regulation of neuropilin-2. Angiogenesis, 16(4), 939–952. https://doi.org/10.1007/s10456-013-9370-9CrossRefPubMedPubMedCentral

29.

German, A. E., Mammoto, T., Jiang, E., Ingber, D. E., & Mammoto, A. (2014). Paxillin controls endothelial cell migration and tumor angiogenesis by altering neuropilin 2 expression. Journal of Cell Science, 127(Pt 8), 1672–1683. https://doi.org/10.1242/jcs.132316CrossRefPubMedPubMedCentral

30.

Fujita, H., Zhang, B., Sato, K., Tanaka, J., & Sakanaka, M. (2001). Expressions of neuropilin-1, neuropilin-2 and semaphorin 3A mRNA in the rat brain after middle cerebral artery occlusion. Brain Research, 914(1–2), 1–14. https://doi.org/10.1016/s0006-8993(01)02765-2CrossRefPubMed

31.

Dallinga, M. G., Habani, Y. I., Schimmel, A. W. M., Dallinga-Thie, G. M., van Noorden, C. J. F., Klaassen, I., Schlingemann, R. O. (2021). The role of heparan sulfate and neuropilin 2 in VEGFA signaling in human endothelial tip cells and non-tip cells during angiogenesis in vitro. Cells. 10(4). https://doi.org/10.3390/cells10040926.

32.

Soker, S., Takashima, S., Miao, H. Q., Neufeld, G., & Klagsbrun, M. (1998). Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell., 92(6), 735–45. https://doi.org/10.1016/s0092-8674(00)81402-6CrossRefPubMed

33.

Hong, Y. K., Harvey, N., Noh, Y. H., Schacht, V., Hirakawa, S., Detmar, M., & Oliver, G. (2002). Prox1 is a master control gene in the program specifying lymphatic endothelial cell fate. Developmental Dynamics, 225(3), 351–357. https://doi.org/10.1002/dvdy.10163CrossRefPubMed

34.

Cohen, T., Herzog, Y., Brodzky, A., Greenson, J. K., Eldar, S., Gluzman-Poltorak, Z., Neufeld, G., & Resnick, M. B. (2002). Neuropilin-2 is a novel marker expressed in pancreatic islet cells and endocrine pancreatic tumours. The Journal of Pathology, 198(1), 77–82. https://doi.org/10.1002/path.1179CrossRefPubMed

35.

Cheppudira, B. P., Girard, B. M., Malley, S. E., Schutz, K. C., May, V., & Vizzard, M. A. (2008). Upregulation of vascular endothelial growth factor isoform VEGF-164 and receptors (VEGFR-2, Npn-1, and Npn-2) in rats with cyclophosphamide-induced cystitis. American Journal of Physiology. Renal Physiology, 295(3), F826–F836. https://doi.org/10.1152/ajprenal.90305.2008CrossRefPubMedPubMedCentral

36.

Saban, M. R., Sferra, T. J., Davis, C. A., Simpson, C., Allen, A., Maier, J., Fowler, B., Knowlton, N., Birder, L., Wu, X. R., & Saban, R. (2010). Neuropilin-VEGF signaling pathway acts as a key modulator of vascular, lymphatic, and inflammatory cell responses of the bladder to intravesical BCG treatment. American Journal of Physiology Renal Physiology, 299(6), F1245–F1256. https://doi.org/10.1152/ajprenal.00352.2010CrossRefPubMed

37.

Man, X. Y., Yang, X. H., Cai, S. Q., Yao, Y. G., & Zheng, M. (2006). Immunolocalization and expression of vascular endothelial growth factor receptors (VEGFRs) and neuropilins (NRPs) on keratinocytes in human epidermis. Molecular Medicine, 12(7–8), 127–136. https://doi.org/10.2119/2006-00024.ManCrossRefPubMedPubMedCentral

38.

Drenberg, C. D., Livingston, S., Chen, R., Kruk, P. A., & Nicosia, S. V. (2009). Expression of semaphorin 3F and its receptors in epithelial ovarian cancer, fallopian tubes, and secondary mullerian tissues. Obstetrics and Gynecology International, 2009, 730739. https://doi.org/10.1155/2009/730739CrossRefPubMedPubMedCentral

39.

Cohen, T., Gluzman-Poltorak, Z., Brodzky, A., Meytal, V., Sabo, E., Misselevich, I., Hassoun, M., Boss, J. H., Resnick, M., Shneyvas, D., Eldar, S., & Neufeld, G. (2001). Neuroendocrine cells along the digestive tract express neuropilin-2. Biochemical and Biophysical Research Communications, 284(2), 395–403. https://doi.org/10.1006/bbrc.2001.4958CrossRefPubMed

40.

Hansel, D. E., Wilentz, R. E., Yeo, C. J., Schulick, R. D., Montgomery, E., & Maitra, A. (2004). Expression of neuropilin-1 in high-grade dysplasia, invasive cancer, and metastases of the human gastrointestinal tract. American Journal of Surgical Pathology, 28(3), 347–356. https://doi.org/10.1097/00000478-200403000-00007CrossRefPubMed

41.

Jubb, A. M., Sa, S. M., Ratti, N., Strickland, L. A., Schmidt, M., Callahan, C. A., & Koeppen, H. (2012). Neuropilin-2 expression in cancer. Histopathology, 61(3), 340–349. https://doi.org/10.1111/j.1365-2559.2012.04224.xCrossRefPubMed

42.

Verlinden, L., Kriebitzsch, C., Beullens, I., Tan, B. K., Carmeliet, G., & Verstuyf, A. (2013). Nrp2 deficiency leads to trabecular bone loss and is accompanied by enhanced osteoclast and reduced osteoblast numbers. Bone, 55(2), 465–475. https://doi.org/10.1016/j.bone.2013.03.023CrossRefPubMed

43.

Borkowetz, A., Froehner, M., Rauner, M., Conrad, S., Erdmann, K., Mayr, T., Datta, K., Hofbauer, L. C., Baretton, G. B., Wirth, M., Fuessel, S., Toma, M., & Muders, M. H. (2020). Neuropilin-2 is an independent prognostic factor for shorter cancer-specific survival in patients with acinar adenocarcinoma of the prostate. International Journal of Cancer, 146(9), 2619–2627. https://doi.org/10.1002/ijc.32679CrossRefPubMed

44.

Handa, A., Tokunaga, T., Tsuchida, T., Lee, Y. H., Kijima, H., Yamazaki, H., Ueyama, Y., Fukuda, H., & Nakamura, M. (2000). Neuropilin-2 expression affects the increased vascularization and is a prognostic factor in osteosarcoma. International Journal of Oncology, 17(2), 291–295. https://doi.org/10.3892/ijo.17.2.291CrossRefPubMed

45.

Kawakami, T., Tokunaga, T., Hatanaka, H., Kijima, H., Yamazaki, H., Abe, Y., Osamura, Y., Inoue, H., Ueyama, Y., & Nakamura, M. (2002). Neuropilin 1 and neuropilin 2 co-expression is significantly correlated with increased vascularity and poor prognosis in nonsmall cell lung carcinoma. Cancer, 95(10), 2196–2201. https://doi.org/10.1002/cncr.10936CrossRefPubMed

46.

Osada, R., Horiuchi, A., Kikuchi, N., Ohira, S., Ota, M., Katsuyama, Y., & Konishi, I. (2006). Expression of semaphorins, vascular endothelial growth factor, and their common receptor neuropilins and alleic loss of semaphorin locus in epithelial ovarian neoplasms: Increased ratio of vascular endothelial growth factor to semaphorin is a poor prognostic factor in ovarian carcinomas. Human Pathology, 37(11), 1414–1425. https://doi.org/10.1016/j.humpath.2006.04.031CrossRefPubMed

47.

Yasuoka, H., Kodama, R., Tsujimoto, M., Yoshidome, K., Akamatsu, H., Nakahara, M., Inagaki, M., Sanke, T., & Nakamura, Y. (2009). Neuropilin-2 expression in breast cancer: Correlation with lymph node metastasis, poor prognosis, and regulation of CXCR4 expression. BMC Cancer, 9, 220. https://doi.org/10.1186/1471-2407-9-220CrossRefPubMedPubMedCentral

48.

Fakhari, M., Pullirsch, D., Abraham, D., Paya, K., Hofbauer, R., Holzfeind, P., Hofmann, M., & Aharinejad, S. (2002). Selective upregulation of vascular endothelial growth factor receptors neuropilin-1 and -2 in human neuroblastoma. Cancer, 94(1), 258–263. https://doi.org/10.1002/cncr.10177CrossRefPubMed

49.

Wittmann, P., Grubinger, M., Groger, C., Huber, H., Sieghart, W., Peck-Radosavljevic, M., & Mikulits, W. (2015). Neuropilin-2 induced by transforming growth factor-beta augments migration of hepatocellular carcinoma cells. BMC Cancer, 15, 909. https://doi.org/10.1186/s12885-015-1919-0CrossRefPubMedPubMedCentral

50.

Evanno, E., Godet, J., Piccirilli, N., Guilhot, J., Milin, S., Gombert, J. M., Fouchaq, B., & Roche, J. (2017). Tri-methylation of H3K79 is decreased in TGF-beta1-induced epithelial-to-mesenchymal transition in lung cancer. Clinical Epigenetics, 9, 80. https://doi.org/10.1186/s13148-017-0380-0CrossRefPubMedPubMedCentral

51.

Gemmill, R. M., Nasarre, P., Nair-Menon, J., Cappuzzo, F., Landi, L., D'Incecco, A., Uramoto, H., Yoshida, T., Haura, E.B., Armeson, K., Drabkin, H. A. (2017). The neuropilin 2 isoform NRP2b uniquely supports TGFbeta-mediated progression in lung cancer. Science Signaling, 10(462). https://doi.org/10.1126/scisignal.aag0528.

52.

Zhao, M., Zhang, M., Tao, Z., Cao, J., Wang, L., & Hu, X. (2020). miR-331-3p Suppresses cell proliferation in TNBC cells by downregulating NRP2. Technology in Cancer Research & Treatment, 19, 1533033820905824. https://doi.org/10.1177/1533033820905824CrossRef

53.

Epis, M. R., Giles, K. M., Candy, P. A., Webster, R. J., & Leedman, P. J. (2014). miR-331-3p regulates expression of neuropilin-2 in glioblastoma. Journal of Neuro-oncology, 116(1), 67–75. https://doi.org/10.1007/s11060-013-1271-7CrossRefPubMed

54.

Do, Y., Cho, J. G., Park, J. Y., Oh, S., Park, D., Yoo, K. H., Lee, M. S., Kwon, B. S., Kim, J., Yang, Y. (2020). MiR-146a Regulates migration and invasion by targeting NRP2 in circulating-tumor cell mimicking suspension cells. Genes (Basel), 12(1). https://doi.org/10.3390/genes12010045.

55.

Chen, Y., Huang, S., Wu, B., Fang, J., Zhu, M., Sun, L., Zhang, L., Zhang, Y., Sun, M., Guo, L., & Wang, S. (2017). Transforming growth factor-beta1 promotes breast cancer metastasis by downregulating miR-196a-3p expression. Oncotarget, 8(30), 49110–49122. https://doi.org/10.18632/oncotarget.16308CrossRefPubMedPubMedCentral

56.

Liu, C., Li, M., Hu, Y., Shi, N., Yu, H., Liu, H., & Lian, H. (2016). miR-486-5p attenuates tumor growth and lymphangiogenesis by targeting neuropilin-2 in colorectal carcinoma. Oncotargets and Therapy, 9, 2865–2871. https://doi.org/10.2147/OTT.S103460CrossRefPubMedPubMedCentral

57.

Liu, A., Liu, L., & Lu, H. (2019). LncRNA XIST facilitates proliferation and epithelial-mesenchymal transition of colorectal cancer cells through targeting miR-486-5p and promoting neuropilin-2. Journal of Cellular Physiology, 234(8), 13747–13761. https://doi.org/10.1002/jcp.28054CrossRefPubMed

58.

Wang, Y., Yin, H., & Chen, X. (2021). Circ-LDLRAD3 Enhances cell growth, migration, and invasion and inhibits apoptosis by regulating MiR-224-5p/NRP2 axis in gastric cancer. Digestive Diseases and Sciences, 66(11), 3862–3871. https://doi.org/10.1007/s10620-020-06733-1CrossRefPubMed

59.

Cobos, I., Borello, U., & Rubenstein, J. L. (2007). Dlx transcription factors promote migration through repression of axon and dendrite growth. Neuron, 54(6), 873–888. https://doi.org/10.1016/j.neuron.2007.05.024CrossRefPubMedPubMedCentral

60.

Yilmaz, M., Maass, D., Tiwari, N., Waldmeier, L., Schmidt, P., Lehembre, F., & Christofori, G. (2011). Transcription factor Dlx2 protects from TGFbeta-induced cell-cycle arrest and apoptosis. EMBO Journal, 30(21), 4489–4499. https://doi.org/10.1038/emboj.2011.319CrossRefPubMedPubMedCentral

61.

Ghanem, N., Andrusiak, M. G., Svoboda, D., Al Lafi, S. M., Julian, L. M., McClellan, K. A., De Repentigny, Y., Kothary, R., Ekker, M., Blais, A., Park, D. S., & Slack, R. S. (2012). The Rb/E2F pathway modulates neurogenesis through direct regulation of the Dlx1/Dlx2 bigene cluster. Journal of Neuroscience, 32(24), 8219–8230. https://doi.org/10.1523/JNEUROSCI.1344-12.2012CrossRefPubMed

62.

Park, D. H., Hong, S. J., Salinas, R. D., Liu, S. J., Sun, S. W., Sgualdino, J., Testa, G., Matzuk, M. M., Iwamori, N., & Lim, D. A. (2014). Activation of neuronal gene expression by the JMJD3 demethylase is required for postnatal and adult brain neurogenesis. Cell Reports, 8(5), 1290–1299. https://doi.org/10.1016/j.celrep.2014.07.060CrossRefPubMed

63.

Morini, M., Astigiano, S., Gitton, Y., Emionite, L., Mirisola, V., Levi, G., & Barbieri, O. (2010). Mutually exclusive expression of DLX2 and DLX5/6 is associated with the metastatic potential of the human breast cancer cell line MDA-MB-231. BMC Cancer, 10, 649. https://doi.org/10.1186/1471-2407-10-649CrossRefPubMedPubMedCentral

64.

Samuel, S., & Naora, H. (2005). Homeobox gene expression in cancer: Insights from developmental regulation and deregulation. European Journal of Cancer, 41(16), 2428–2437. https://doi.org/10.1016/j.ejca.2005.08.014CrossRefPubMed

65.

Ferrari, N., Palmisano, G. L., Paleari, L., Basso, G., Mangioni, M., Fidanza, V., Albini, A., Croce, C. M., Levi, G., & Brigati, C. (2003). DLX genes as targets of ALL-1: DLX 2,3,4 down-regulation in t(4;11) acute lymphoblastic leukemias. Journal of Leukocyte Biology, 74(2), 302–305. https://doi.org/10.1189/jlb.1102581CrossRefPubMed

66.

Lv, T., Wu, X., Sun, L., Hu, Q., Wan, Y., Wang, L., Zhao, Z., Tu, X., & Xiao, Z. J. (2017). p53–R273H upregulates neuropilin-2 to promote cell mobility and tumor metastasis. Cell Death & Disease, 8(8), e2995. https://doi.org/10.1038/cddis.2017.376CrossRef

67.

Ji, T., Guo, Y., Kim, K., McQueen, P., Ghaffar, S., Christ, A., Lin, C., Eskander, R., Zi, X., & Hoang, B. H. (2015). Neuropilin-2 expression is inhibited by secreted Wnt antagonists and its down-regulation is associated with reduced tumor growth and metastasis in osteosarcoma. Molecular Cancer, 14, 86. https://doi.org/10.1186/s12943-015-0359-4CrossRefPubMedPubMedCentral

68.

Lucci, V., Di Palma, T., & Zannini, M. (2015). Neuropilin-2 Is a newly identified target of PAX8 in thyroid cells. PLoS One, 10(6), e0128315. https://doi.org/10.1371/journal.pone.0128315CrossRefPubMedPubMedCentral

69.

Muders, M. H., Zhang, H., Wang, E., Tindall, D. J., & Datta, K. (2009). Vascular endothelial growth factor-C protects prostate cancer cells from oxidative stress by the activation of mammalian target of rapamycin complex-2 and AKT-1. Cancer Research, 69(15), 6042–6048. https://doi.org/10.1158/0008-5472.CAN-09-0552CrossRefPubMedPubMedCentral

70.

Dutta, S., Roy, S., Polavaram, N. S., Stanton, M. J., Zhang, H., Bhola, T., Honscheid, P., Donohue, T. M., Jr., Band, H., Batra, S. K., Muders, M. H., & Datta, K. (2016). Neuropilin-2 regulates endosome maturation and EGFR trafficking to support cancer cell pathobiology. Cancer Research, 76(2), 418–428. https://doi.org/10.1158/0008-5472.CAN-15-1488CrossRefPubMed

71.

Roy, S., Bag, A. K., Dutta, S., Polavaram, N. S., Islam, R., Schellenburg, S., Banwait, J., Guda, C., Ran, S., Hollingsworth, M. A., Singh, R. K., Talmadge, J. E., Muders, M. H., Batra, S. K., & Datta, K. (2018). Macrophage-derived neuropilin-2 exhibits novel tumor-promoting functions. Cancer Research, 78(19), 5600–5617. https://doi.org/10.1158/0008-5472.CAN-18-0562CrossRefPubMedPubMedCentral

72.

Bagri, A., Tessier-Lavigne, M., & Watts, R. J. (2009). Neuropilins in tumor biology. Clinical Cancer Research, 15(6), 1860–1864.CrossRef

73.

Uniewicz, K. A., & Fernig, D. G. (2008). Neuropilins: A versatile partner of extracellular molecules that regulate development and disease. Frontiers in Bioscience, 13, 4339–4360. https://doi.org/10.2741/3008CrossRefPubMed

74.

Prud’homme, G. J., & Glinka, Y. (2012). Neuropilins are multifunctional coreceptors involved in tumor initiation, growth, metastasis and immunity. Oncotarget, 3(9), 921–939. https://doi.org/10.18632/oncotarget.626CrossRefPubMedPubMedCentral

75.

Roche, J., Boldog, F., Robinson, M., Robinson, L., Varella-Garcia, M., Swanton, M., Waggoner, B., Fishel, R., Franklin, W., Gemmill, R., & Drabkin, H. (1996). Distinct 3p21.3 deletions in lung cancer and identification of a new human semaphorin. Oncogene., 12(6), 1289–97.PubMed

76.

Joseph, D., Ho, S. M., & Syed, V. (2010). Hormonal regulation and distinct functions of semaphorin-3B and semaphorin-3F in ovarian cancer. Molecular Cancer Therapeutics, 9(2), 499–509. https://doi.org/10.1158/1535-7163.MCT-09-0664CrossRefPubMedPubMedCentral

77.

Chabbert-de Ponnat, I., Buffard, V., Leroy, K., Bagot, M., Bensussan, A., Wolkenstein, P., & Marie-Cardine, A. (2006). Antiproliferative effect of semaphorin 3F on human melanoma cell lines. The Journal of Investigative Dermatology, 126(10), 2343–2345. https://doi.org/10.1038/sj.jid.5700382CrossRefPubMed

78.

Nasarre, P., Kusy, S., Constantin, B., Castellani, V., Drabkin, H. A., Bagnard, D., & Roche, J. (2005). Semaphorin SEMA3F has a repulsing activity on breast cancer cells and inhibits E-cadherin-mediated cell adhesion. Neoplasia, 7(2), 180–189. https://doi.org/10.1593/neo.04481CrossRefPubMedPubMedCentral

79.

Neufeld, G., & Kessler, O. (2008). The semaphorins: Versatile regulators of tumour progression and tumour angiogenesis. Nature Reviews Cancer, 8(8), 632–645. https://doi.org/10.1038/nrc2404CrossRefPubMed

80.

Potiron, V. A., Sharma, G., Nasarre, P., Clarhaut, J. A., Augustin, H. G., Gemmill, R. M., Roche, J., & Drabkin, H. A. (2007). Semaphorin SEMA3F affects multiple signaling pathways in lung cancer cells. Cancer Research, 67(18), 8708–8715. https://doi.org/10.1158/0008-5472.CAN-06-3612CrossRefPubMed

81.

Sulpice, E., Plouet, J., Berge, M., Allanic, D., Tobelem, G., & Merkulova-Rainon, T. (2008). Neuropilin-1 and neuropilin-2 act as coreceptors, potentiating proangiogenic activity. Blood, 111(4), 2036–2045. https://doi.org/10.1182/blood-2007-04-084269CrossRefPubMed

82.

Matsushita, A., Gotze, T., & Korc, M. (2007). Hepatocyte growth factor-mediated cell invasion in pancreatic cancer cells is dependent on neuropilin-1. Cancer Research, 67(21), 10309–10316. https://doi.org/10.1158/0008-5472.CAN-07-3256CrossRefPubMed

83.

Hu, B., Guo, P., Bar-Joseph, I., Imanishi, Y., Jarzynka, M. J., Bogler, O., Mikkelsen, T., Hirose, T., Nishikawa, R., & Cheng, S. Y. (2007). Neuropilin-1 promotes human glioma progression through potentiating the activity of the HGF/SF autocrine pathway. Oncogene, 26(38), 5577–5586. https://doi.org/10.1038/sj.onc.1210348CrossRefPubMedPubMedCentral

84.

Pellet-Many, C., Mehta, V., Fields, L., Mahmoud, M., Lowe, V., Evans, I., Ruivo, J., & Zachary, I. (2015). Neuropilins 1 and 2 mediate neointimal hyperplasia and re-endothelialization following arterial injury. Cardiovascular Research, 108(2), 288–298. https://doi.org/10.1093/cvr/cvv229CrossRefPubMedPubMedCentral

85.

Glinka, Y., Stoilova, S., Mohammed, N., & Prud’homme, G. J. (2011). Neuropilin-1 exerts co-receptor function for TGF-beta-1 on the membrane of cancer cells and enhances responses to both latent and active TGF-beta. Carcinogenesis, 32(4), 613–621. https://doi.org/10.1093/carcin/bgq281CrossRefPubMed

86.

Young, G. D., & Murphy-Ullrich, J. E. (2004). Molecular interactions that confer latency to transforming growth factor-beta. Journal of Biological Chemistry, 279(36), 38032–38039. https://doi.org/10.1074/jbc.M405658200CrossRefPubMed

87.

Grandclement, C., Pallandre, J. R., Valmary Degano, S., Viel, E., Bouard, A., Balland, J., Remy-Martin, J. P., Simon, B., Rouleau, A., Boireau, W., Klagsbrun, M., Ferrand, C., & Borg, C. (2011). Neuropilin-2 expression promotes TGF-beta1-mediated epithelial to mesenchymal transition in colorectal cancer cells. PLoS One, 6(7), e20444. https://doi.org/10.1371/journal.pone.0020444CrossRefPubMedPubMedCentral

88.

Guarino, M. (2007). Epithelial-mesenchymal transition and tumour invasion. International Journal of Biochemistry & Cell Biology, 39(12), 2153–2160. https://doi.org/10.1016/j.biocel.2007.07.011CrossRef

89.

Samuel, S., Gaur, P., Fan, F., Xia, L., Gray, M. J., Dallas, N. A., Bose, D., Rodriguez-Aguayo, C., Lopez-Berestein, G., Plowman, G., Bagri, A., Sood, A. K., & Ellis, L. M. (2011). Neuropilin-2 mediated beta-catenin signaling and survival in human gastro-intestinal cancer cell lines. PLoS One, 6(10), e23208. https://doi.org/10.1371/journal.pone.0023208CrossRefPubMedPubMedCentral

90.

Gray, M. J., Van Buren, G., Dallas, N. A., Xia, L., Wang, X., Yang, A. D., Somcio, R. J., Lin, Y. G., Lim, S., Fan, F., Mangala, L. S., Arumugam, T., Logsdon, C. D., Lopez-Berestein, G., Sood, A. K., & Ellis, L. M. (2008). Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver. Journal of the National Cancer Institute, 100(2), 109–120. https://doi.org/10.1093/jnci/djm279CrossRefPubMed

91.

Dallas, N. A., Gray, M. J., Xia, L., Fan, F., van Buren, G., II., Gaur, P., Samuel, S., Lim, S. J., Arumugam, T., Ramachandran, V., Wang, H., & Ellis, L. M. (2008). Neuropilin-2-mediated tumor growth and angiogenesis in pancreatic adenocarcinoma. Clin Cancer Res., 14(24), 8052–60. https://doi.org/10.1158/1078-0432.CCR-08-1520CrossRefPubMed

92.

Kim, W. H., Lee, S. H., Jung, M. H., Seo, J. H., Kim, J., Kim, M. A., & Lee, Y. M. (2009). Neuropilin2 expressed in gastric cancer endothelial cells increases the proliferation and migration of endothelial cells in response to VEGF. Experimental Cell Research, 315(13), 2154–2164. https://doi.org/10.1016/j.yexcr.2009.04.018CrossRefPubMed

93.

Alghamdi, A. A. A., Benwell, C. J., Atkinson, S. J., Lambert, J., Johnson, R. T., & Robinson, S. D. (2020). NRP2 as an emerging angiogenic player; promoting endothelial cell adhesion and migration by regulating recycling of alpha5 integrin. Frontiers in Cell and Development Biology, 8, 395. https://doi.org/10.3389/fcell.2020.00395CrossRef

94.

Roy, S., Bag, A. K., Singh, R. K., Talmadge, J. E., Batra, S. K., & Datta, K. (2017). Multifaceted role of neuropilins in the immune system: Potential targets for immunotherapy. Frontiers in Immunology, 8, 1228. https://doi.org/10.3389/fimmu.2017.01228CrossRefPubMedPubMedCentral

95.

Goel, H. L., Chang, C., Pursell, B., Leav, I., Lyle, S., Xi, H. S., Hsieh, C. C., Adisetiyo, H., Roy-Burman, P., Coleman, I. M., Nelson, P. S., Vessella, R. L., Davis, R. J., Plymate, S. R., & Mercurio, A. M. (2012). VEGF/neuropilin-2 regulation of Bmi-1 and consequent repression of IGF-IR define a novel mechanism of aggressive prostate cancer. Cancer Discovery, 2(10), 906–921. https://doi.org/10.1158/2159-8290.CD-12-0085CrossRefPubMedPubMedCentral

96.

Polavaram, N. S., Dutta, S., Islam, R., Bag, A. K., Roy, S., Poitz, D., Karnes, J., Hofbauer, L. C., Kohli, M., Costello, B. A., Jimenez, R., Batra, S. K., Teply, B. A., Muders, M. H., & Datta, K. (2021). Tumor- and osteoclast-derived NRP2 in prostate cancer bone metastases. Bone Research, 9(1), 24. https://doi.org/10.1038/s41413-021-00136-2CrossRefPubMedPubMedCentral

97.

Halabi, S., Kelly, W. K., Ma, H., Zhou, H., Solomon, N. C., Fizazi, K., Tangen, C. M., Rosenthal, M., Petrylak, D. P., Hussain, M., Vogelzang, N. J., Thompson, I. M., Chi, K. N., de Bono, J., Armstrong, A. J., Eisenberger, M. A., Fandi, A., Li, S., Araujo, J. C., … Small, E. J. (2016). Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer. Journal of Clinical Oncology, 34(14), 1652–1659. https://doi.org/10.1200/JCO.2015.65.7270CrossRefPubMedPubMedCentral

98.

Abida, W., Cyrta, J., Heller, G., Prandi, D., Armenia, J., Coleman, I., Cieslik, M., Benelli, M., Robinson, D., Van Allen, E. M., Sboner, A., Fedrizzi, T., Mosquera, J. M., Robinson, B. D., De Sarkar, N., Kunju, L. P., Tomlins, S., Wu, Y. M., Nava Rodrigues, D., … Sawyers, C. L. (2019). Genomic correlates of clinical outcome in advanced prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 116(23), 11428–11436. https://doi.org/10.1073/pnas.1902651116CrossRefPubMedPubMedCentral

99.

Stanton, M. J., Dutta, S., Zhang, H., Polavaram, N. S., Leontovich, A. A., Honscheid, P., Sinicrope, F. A., Tindall, D. J., Muders, M. H., & Datta, K. (2013). Autophagy control by the VEGF-C/NRP-2 axis in cancer and its implication for treatment resistance. Cancer Research, 73(1), 160–171. https://doi.org/10.1158/0008-5472.CAN-11-3635CrossRefPubMed

100.

Dutta, S., Roy, S., Polavaram, N. S., Baretton, G. B., Muders, M. H., Batra, S., & Datta, K. (2016). NRP2 transcriptionally regulates its downstream effector WDFY1. Science and Reports, 6, 23588. https://doi.org/10.1038/srep23588CrossRef

101.

Dutta, S. P. N., Islam, R., Bhattacharya, S., Bodas, S., Mayr, T., Roy, S., Albala, S. Y., Toma, M. I., Darehshouri, A., Borkowetz, A., Conrad, S., Fuessel, S., Wirth, M., Baretton, G., Hofbauer, L., Ghosh, P., Pienta, K. J., Klinkebiel, D., Batra, S. K., Muders, M. H., Datta, K. (2022). Neuropilin-2 regulates androgen-receptor transcriptional activity in advanced prostate cancer. Oncogene.

102.

Goel, H. L., Pursell, B., Shultz, L. D., Greiner, D. L., Brekken, R. A., Vander Kooi, C. W., & Mercurio, A. M. (2016). P-Rex1 promotes resistance to VEGF/VEGFR-targeted therapy in prostate cancer. Cell Reports, 14(9), 2193–2208. https://doi.org/10.1016/j.celrep.2016.02.016CrossRefPubMed

103.

Islam, R. M., J. Polavaram, N. Bhattacharya, S. Hong, Z, Bodas, S. Sharma, S. Bouska, A. Gilbreath, T. Said, A. Smith, L. M. Teply, B. A. Muders, M. H. Batra, S. K. Datta, K. Dutta, S (2022). Neuropilin-2 axis in regulating secretory phenotype of neuroendocrine-like prostate cancer cells: Implication in therapy resistance. Cell Reports.

104.

Keck, B., Wach, S., Taubert, H., Zeiler, S., Ott, O. J., Kunath, F., Hartmann, A., Bertz, S., Weiss, C., Honscheid, P., Schellenburg, S., Rodel, C., Baretton, G. B., Sauer, R., Fietkau, R., Wullich, B., Krause, F. S., Datta, K., & Muders, M. H. (2015). Neuropilin-2 and its ligand VEGF-C predict treatment response after transurethral resection and radiochemotherapy in bladder cancer patients. International Journal of Cancer, 136(2), 443–451. https://doi.org/10.1002/ijc.28987CrossRefPubMed

105.

Forster, S., Givehchi, M., Nitschke, K., Mayr, T., Kilian, K., Dutta, S., Datta, K., Nuhn, P., Popovic, Z., Muders, M. H., Erben, P. (2021). Neuropilin-2 and its transcript variants correlate with clinical outcome in bladder cancer. Genes (Basel), 12(4). https://doi.org/10.3390/genes12040550.

106.

Deng, C., Guo, H., Yan, D., Liang, T., Ye, X., & Li, Z. (2021). Pancancer analysis of neurovascular-related NRP family genes as potential prognostic biomarkers of bladder urothelial carcinoma. BioMed Research International, 2021, 5546612. https://doi.org/10.1155/2021/5546612CrossRefPubMedPubMedCentral

107.

Schulz, A., Gorodetska, I., Behrendt, R., Fuessel, S., Erdmann, K., Foerster, S., Datta, K., Mayr, T., Dubrovska, A., & Muders, M. H. (2019). Linking NRP2 With EMT and chemoradioresistance in bladder cancer. Frontiers in Oncology, 9, 1461. https://doi.org/10.3389/fonc.2019.01461CrossRefPubMed

108.

Cao, Y., Hoeppner, L. H., Bach, S., Guangqi, E., Guo, Y., Wang, E., Wu, J., Cowley, M. J., Chang, D. K., Waddell, N., Grimmond, S. M., Biankin, A. V., Daly, R. J., Zhang, X., & Mukhopadhyay, D. (2013). Neuropilin-2 promotes extravasation and metastasis by interacting with endothelial alpha5 integrin. Cancer Research, 73(14), 4579–90. https://doi.org/10.1158/0008-5472.CAN-13-0529CrossRefPubMedPubMedCentral

109.

Cetin, B., Gonul, I. I., Buyukberber, S., Afsar, B., Gumusay, O., Algin, E., Turan, N., Ozet, A., Benekli, M., & Coskun, U. (2015). The impact of immunohistochemical staining with ezrin-carbonic anhydrase IX and neuropilin-2 on prognosis in patients with metastatic renal cell cancer receiving tyrosine kinase inhibitors. Tumour Biology, 36(11), 8471–8478. https://doi.org/10.1007/s13277-015-3589-6CrossRefPubMed

110.

Bollard, J., Patte, C., Radkova, K., Massoma, P., Chardon, L., Valantin, J., Gadot, N., Goddard, I., Vercherat, C., Hervieu, V., Gouysse, G., Poncet, G., Scoazec, J. Y., Walter, T., & Roche, C. (2019). Neuropilin-2 contributes to tumor progression in preclinical models of small intestinal neuroendocrine tumors. The Journal of Pathology, 249(3), 343–355. https://doi.org/10.1002/path.5321CrossRefPubMed

111.

Dong, X., Guo, W., Zhang, S., Wu, T., Sun, Z., Yan, S., & Zheng, S. (2017). Elevated expression of neuropilin-2 associated with unfavorable prognosis in hepatocellular carcinoma. Oncotargets and Therapy, 10, 3827–3833. https://doi.org/10.2147/OTT.S139044CrossRefPubMedPubMedCentral

112.

Eloranta, K., Nousiainen, R., Cairo, S., Pakarinen, M. P., Wilson, D. B., Pihlajoki, M., & Heikinheimo, M. (2021). Neuropilin-2 is associated with increased hepatoblastoma cell viability and motility. Frontiers in Pediatrics, 9, 660482. https://doi.org/10.3389/fped.2021.660482CrossRefPubMedPubMedCentral

113.

Fukahi, K., Fukasawa, M., Neufeld, G., Itakura, J., & Korc, M. (2004). Aberrant expression of neuropilin-1 and -2 in human pancreatic cancer cells. Clinical Cancer Research, 10(2), 581–590. https://doi.org/10.1158/1078-0432.ccr-0930-03CrossRefPubMed

114.

Wang, L., Wang, L., Wang, S., Zhou, Z., Liu, Z., Xu, P., Luo, X., Wu, T., Luo, F., & Yan, J. (2021). N2E4, a Monoclonal antibody targeting neuropilin-2, inhibits tumor growth and metastasis in pancreatic ductal adenocarcinoma via suppressing FAK/Erk/HIF-1alpha signaling. Frontiers in Oncology, 11, 657008. https://doi.org/10.3389/fonc.2021.657008CrossRefPubMedPubMedCentral

115.

Li, M., Zhang, Y., Feurino, L. W., Wang, H., Fisher, W. E., Brunicardi, F. C., Chen, C., & Yao, Q. (2008). Interleukin-8 increases vascular endothelial growth factor and neuropilin expression and stimulates ERK activation in human pancreatic cancer. Cancer Science, 99(4), 733–737. https://doi.org/10.1111/j.1349-7006.2008.00740.xCrossRefPubMed

116.

Marimuthu, S. L. I., Muniyan, S., Gautam, S., Nimmakayala, R. K., Rauth, S., Atri, P., Shah, A., Bhyravbhatla, N., Mallya, K., Grandgenett, P., Hollingsworth, M., Datta, K., Jain, M., Ponnusamy, M., and Batra, S. K. (2022). MUC16 promotes liver metastasis of pancreatic ductal adenocarcinoma by upregulating NRP2 associated cell adhesion molecular cancer research.

117.

Wu, F., Zhou, Q., Yang, J., Duan, G. J., Ou, J. J., Zhang, R., Pan, F., Peng, Q. P., Tan, H., Ping, Y. F., Cui, Y. H., Qian, C., Yan, X. C., & Bian, X. W. (2011). Endogenous axon guiding chemorepulsant semaphorin-3F inhibits the growth and metastasis of colorectal carcinoma. Clinical Cancer Research, 17(9), 2702–2711. https://doi.org/10.1158/1078-0432.CCR-10-0839CrossRefPubMed

118.

Zhao, H., Hou, C., Hou, A., & Zhu, D. (2016). Concurrent expression of VEGF-C and neuropilin-2 is correlated with poor prognosis in glioblastoma. Tohoku Journal of Experimental Medicine, 238(2), 85–91. https://doi.org/10.1620/tjem.238.85CrossRefPubMed

119.

Zheng, X., Chopp, M., Lu, Y., Buller, B., & Jiang, F. (2013). MiR-15b and miR-152 reduce glioma cell invasion and angiogenesis via NRP-2 and MMP-3. Cancer Letters, 329(2), 146–154. https://doi.org/10.1016/j.canlet.2012.10.026CrossRefPubMed

120.

Nasarre, C., Koncina, E., Labourdette, G., Cremel, G., Roussel, G., Aunis, D., & Bagnard, D. (2009). Neuropilin-2 acts as a modulator of Sema3A-dependent glioma cell migration. Cell Adhesion & Migration, 3(4), 383–9. https://doi.org/10.4161/cam.3.4.9934CrossRef

121.

Timoshenko, A. V., Rastogi, S., & Lala, P. K. (2007). Migration-promoting role of VEGF-C and VEGF-C binding receptors in human breast cancer cells. British Journal of Cancer, 97(8), 1090–1098. https://doi.org/10.1038/sj.bjc.6603993CrossRefPubMedPubMedCentral

122.

Goel, H. L., Pursell, B., Chang, C., Shaw, L. M., Mao, J., Simin, K., Kumar, P., Vander Kooi, C. W., Shultz, L. D., Greiner, D. L., Norum, J. H., Toftgard, R., Kuperwasser, C., & Mercurio, A. M. (2013). GLI1 regulates a novel neuropilin-2/alpha6beta1 integrin based autocrine pathway that contributes to breast cancer initiation. EMBO Molecular Medicine, 5(4), 488–508. https://doi.org/10.1002/emmm.201202078CrossRefPubMedPubMedCentral

123.

Elaimy, A. L., Guru, S., Chang, C., Ou, J., Amante, J. J., Zhu, L. J., Goel, H. L., Mercurio, A. M. (2018). VEGF-neuropilin-2 signaling promotes stem-like traits in breast cancer cells by TAZ-mediated repression of the Rac GAP beta2-chimaerin. Science Signaling, 11(528). https://doi.org/10.1126/scisignal.aao6897.

124.

Goel, H. L., Pursell, B., Standley, C., Fogarty, K., & Mercurio, A. M. (2012). Neuropilin-2 regulates alpha6beta1 integrin in the formation of focal adhesions and signaling. Journal of Cell Science, 125(Pt 2), 497–506. https://doi.org/10.1242/jcs.094433CrossRefPubMedPubMedCentral

125.

Elaimy, A. L., Amante, J. J., Zhu, L. J., Wang, M., Walmsley, C. S., FitzGerald, T. J., Goel, H. L., & Mercurio, A. M. (2019). The VEGF receptor neuropilin 2 promotes homologous recombination by stimulating YAP/TAZ-mediated Rad51 expression. Proceedings of the National Academy of Sciences of the United States of America, 116(28), 14174–14180. https://doi.org/10.1073/pnas.1821194116CrossRefPubMedPubMedCentral

126.

Rushing, E. C., Stine, M. J., Hahn, S. J., Shea, S., Eller, M. S., Naif, A., Khanna, S., Westra, W. H., Jungbluth, A. A., Busam, K. J., Mahalingam, M., & Alani, R. M. (2012). Neuropilin-2: A novel biomarker for malignant melanoma? Human Pathology, 43(3), 381–389. https://doi.org/10.1016/j.humpath.2011.05.008CrossRefPubMed

127.

Rossi, M., Tuck, J., Kim, O. J., Panova, I., Symanowski, J. T., Mahalingam, M., Riker, A. I., Alani, R. M., & Ryu, B. (2014). Neuropilin-2 gene expression correlates with malignant progression in cutaneous melanoma. British Journal of Dermatology, 171(2), 403–408. https://doi.org/10.1111/bjd.12801CrossRefPubMed

128.

Wititsuwannakul, J., Mason, A. R., Klump, V. R., & Lazova, R. (2013). Neuropilin-2 as a useful marker in the differentiation between Spitzoid malignant melanoma and Spitz nevus. Journal of the American Academy of Dermatology, 68(1), 129–137. https://doi.org/10.1016/j.jaad.2012.07.009CrossRefPubMed

129.

Stine, M. J., Wang, C. J., Moriarty, W. F., Ryu, B., Cheong, R., Westra, W. H., Levchenko, A., & Alani, R. M. (2011). Integration of genotypic and phenotypic screening reveals molecular mediators of melanoma-stromal interaction. Cancer Research, 71(7), 2433–2444. https://doi.org/10.1158/0008-5472.CAN-10-1875CrossRefPubMedPubMedCentral

130.

Moriarty, W. F., Kim, E., Gerber, S. A., Hammers, H., & Alani, R. M. (2016). Neuropilin-2 promotes melanoma growth and progression in vivo. Melanoma Research, 26(4), 321–328. https://doi.org/10.1097/CMR.0000000000000190CrossRefPubMed

131.

Vales, A., Kondo, R., Aichberger, K. J., Mayerhofer, M., Kainz, B., Sperr, W. R., Sillaber, C., Jager, U., & Valent, P. (2007). Myeloid leukemias express a broad spectrum of VEGF receptors including neuropilin-1 (NRP-1) and NRP-2. Leukaemia & Lymphoma, 48(10), 1997–2007. https://doi.org/10.1080/10428190701534424CrossRef

132.

Mendes-da-Cruz, D. A., Brignier, A. C., Asnafi, V., Baleydier, F., Messias, C. V., Lepelletier, Y., Bedjaoui, N., Renand, A., Smaniotto, S., Canioni, D., Milpied, P., Balabanian, K., Bousso, P., Lepretre, S., Bertrand, Y., Dombret, H., Ifrah, N., Dardenne, M., Macintyre, E., … Hermine, O. (2014). Semaphorin 3F and neuropilin-2 control the migration of human T-cell precursors. PLoS One, 9(7), e103405. https://doi.org/10.1371/journal.pone.0103405CrossRefPubMedPubMedCentral

133.

Lee, G., Kang, Y. E., Oh, C., Liu, L., Jin, Y., Lim, M. A., Won, H. R., Chang, J. W., & Koo, B. S. (2020). Neuropilin-2 promotes growth and progression of papillary thyroid cancer cells. Auris, Nasus, Larynx, 47(5), 870–880. https://doi.org/10.1016/j.anl.2020.03.013CrossRefPubMed

134.

Finley, D. J., Arora, N., Zhu, B., Gallagher, L., & Fahey, T. J., 3rd. (2004). Molecular profiling distinguishes papillary carcinoma from benign thyroid nodules. Journal of Clinical Endocrinology and Metabolism, 89(7), 3214–3223. https://doi.org/10.1210/jc.2003-031811CrossRefPubMed

135.

Tu, D. G., Chang, W. W., Jan, M. S., Tu, C. W., Lu, Y. C., & Tai, C. K. (2016). Promotion of metastasis of thyroid cancer cells via NRP-2-mediated induction. Oncology Letters, 12(5), 4224–4230. https://doi.org/10.3892/ol.2016.5153CrossRefPubMedPubMedCentral

136.

Yasuoka, H., Kodama, R., Hirokawa, M., Takamura, Y., Miyauchi, A., Inagaki, M., Sanke, T., & Nakamura, Y. (2011). Neuropilin-2 expression in papillary thyroid carcinoma: Correlation with VEGF-D expression, lymph node metastasis, and VEGF-D-induced aggressive cancer cell phenotype. Journal of Clinical Endocrinology and Metabolism, 96(11), E1857–E1861. https://doi.org/10.1210/jc.2011-1180CrossRefPubMed

137.

Lantuejoul, S., Constantin, B., Drabkin, H., Brambilla, C., Roche, J., & Brambilla, E. (2003). Expression of VEGF, semaphorin SEMA3F, and their common receptors neuropilins NP1 and NP2 in preinvasive bronchial lesions, lung tumours, and cell lines. The Journal of Pathology, 200(3), 336–347. https://doi.org/10.1002/path.1367CrossRefPubMed

138.

Castro-Rivera, E., Ran, S., Thorpe, P., & Minna, J. D. (2004). Semaphorin 3B (SEMA3B) induces apoptosis in lung and breast cancer, whereas VEGF165 antagonizes this effect. Proceedings of the National Academy of Sciences of the United States of America, 101(31), 11432–11437. https://doi.org/10.1073/pnas.0403969101CrossRefPubMedPubMedCentral

139.

Nasarre, P., Gemmill, R. M., Potiron, V. A., Roche, J., Lu, X., Baron, A. E., Korch, C., Garrett-Mayer, E., Lagana, A., Howe, P. H., & Drabkin, H. A. (2013). Neuropilin-2 is upregulated in lung cancer cells during TGF-beta1-induced epithelial-mesenchymal transition. Cancer Research, 73(23), 7111–7121. https://doi.org/10.1158/0008-5472.CAN-13-1755CrossRefPubMedPubMedCentral

140.

Wang, F. Q., Barfield, E., Dutta, S., Pua, T., & Fishman, D. A. (2009). VEGFR-2 silencing by small interference RNA (siRNA) suppresses LPA-induced epithelial ovarian cancer (EOC) invasion. Gynecologic Oncology, 115(3), 414–423. https://doi.org/10.1016/j.ygyno.2009.08.019CrossRefPubMed

141.

Kramer, A., Green, J., Pollard, J., Jr., & Tugendreich, S. (2014). Causal analysis approaches in ingenuity pathway analysis. Bioinformatics, 30(4), 523–530. https://doi.org/10.1093/bioinformatics/btt703CrossRefPubMed

142.

Linneberg, C., Toft, C. L. F., Kjaer-Sorensen, K., & Laursen, L. S. (2019). L1cam-mediated developmental processes of the nervous system are differentially regulated by proteolytic processing. Science and Reports, 9(1), 3716. https://doi.org/10.1038/s41598-019-39884-xCrossRef

143.

Maten, M. V., Reijnen, C., Pijnenborg, J. M. A., Zegers, M. M. (2019). L1 cell adhesion molecule in cancer, a systematic review on domain-specific functions. International Journal of Molecular Sciences 20(17). https://doi.org/10.3390/ijms20174180.

144.

Sakurai, T. (2012). The role of NrCAM in neural development and disorders–Beyond a simple glue in the brain. Molecular and Cellular Neuroscience, 49(3), 351–363. https://doi.org/10.1016/j.mcn.2011.12.002CrossRefPubMed

145.

Wachowiak, R., Mayer, S., Suttkus, A., Martynov, I., Lacher, M., Melling, N., Izbicki, J. R., & Tachezy, M. (2019). CHL1 and NrCAM are primarily expressed in low grade pediatric neuroblastoma. Open Med (Wars)., 14, 920–927. https://doi.org/10.1515/med-2019-0109CrossRefPubMedPubMedCentral

146.

Gorka, B., Skubis-Zegadlo, J., Mikula, M., Bardadin, K., Paliczka, E., & Czarnocka, B. (2007). NrCAM, a neuronal system cell-adhesion molecule, is induced in papillary thyroid carcinomas. British Journal of Cancer, 97(4), 531–538. https://doi.org/10.1038/sj.bjc.6603915CrossRefPubMedPubMedCentral

147.

Ling, X. H., Fu, H., Chen, Z. Y., Lu, J. M., Zhuo, Y. J., Chen, J. H., Zhong, W. D., & Jia, Z. (2019). miR505 suppresses prostate cancer progression by targeting NRCAM. Oncology Reports, 42(3), 991–1004. https://doi.org/10.3892/or.2019.7231CrossRefPubMedPubMedCentral

148.

Bendor, J. T., Logan, T. P., & Edwards, R. H. (2013). The function of alpha-synuclein. Neuron., 79(6), 1044–66. https://doi.org/10.1016/j.neuron.2013.09.004CrossRefPubMed

149.

Lerias, J. R., Pinto, M. C., Botelho, H. M., Awatade, N. T., Quaresma, M. C., Silva, I. A. L., Wanitchakool, P., Schreiber, R., Pepperkok, R., Kunzelmann, K., & Amaral, M. D. (2018). A novel microscopy-based assay identifies extended synaptotagmin-1 (ESYT1) as a positive regulator of anoctamin 1 traffic. Biochimica et Biophysica Acta, Molecular Cell Research, 1865(2), 421–431. https://doi.org/10.1016/j.bbamcr.2017.11.009CrossRefPubMed

150.

Rondas, D., Tomas, A., & Halban, P. A. (2011). Focal adhesion remodeling is crucial for glucose-stimulated insulin secretion and involves activation of focal adhesion kinase and paxillin. Diabetes, 60(4), 1146–1157. https://doi.org/10.2337/db10-0946CrossRefPubMedPubMedCentral

151.

Dominiak, A., Chelstowska, B., Olejarz, W., Nowicka, G. (2020). Communication in the cancer microenvironment as a target for therapeutic interventions. Cancers (Basel), 12(5). https://doi.org/10.3390/cancers12051232.

152.

Parker, M. W., & Vander Kooi, C. W. (2014). Microplate-based screening for small molecule inhibitors of neuropilin-2/vascular endothelial growth factor-C interactions. Analytical Biochemistry, 453, 4–6. https://doi.org/10.1016/j.ab.2014.02.017CrossRefPubMedPubMedCentral

153.

Said, A. M., Parker, M. W., & Vander Kooi, C. W. (2020). Design, synthesis, and evaluation of a novel benzamidine-based inhibitor of VEGF-C binding to neuropilin-2. Bioorganic Chemistry, 100, 103856. https://doi.org/10.1016/j.bioorg.2020.103856CrossRefPubMedPubMedCentral

Titel: Role of Neuropilin-2-mediated signaling axis in cancer progression and therapy resistance
verfasst von: Ridwan Islam
Juhi Mishra
Sanika Bodas
Sreyashi Bhattacharya
Surinder K. Batra
Samikshan Dutta
Kaustubh Datta
Publikationsdatum: 01.07.2022
Verlag: Springer US
Erschienen in: Cancer and Metastasis Reviews / Ausgabe 3/2022
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-022-10048-0

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Role of Neuropilin-2-mediated signaling axis in cancer progression and therapy resistance

Abstract

Neu im Fachgebiet Onkologie

Bei seelischem Stress sind Checkpoint-Hemmer weniger wirksam

Antikörper mobilisiert Neutrophile gegen Krebs

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Update Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2022

The timing of adiposity and changes in the life course on the risk of cancer

The effect of obesity on adipose-derived stromal cells and adipose tissue and their impact on cancer

Oncobiology and treatment of breast cancer in young women

Clinical interventions to break the obesity and cancer link: a narrative review

The role of bone marrow adipocytes in cancer progression: the impact of obesity

Obesity and cancer

Neu im Fachgebiet Onkologie

Bei seelischem Stress sind Checkpoint-Hemmer weniger wirksam

Antikörper mobilisiert Neutrophile gegen Krebs

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Update Onkologie